Y-Mabs, Inc   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2014)

Organization Overview

First Clinical Trial
2014
NCT01502917
First Marketed Drug
2020
naxitamab (Danyelza)
First NDA Approval
2020
naxitamab (Danyelza)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Y-mAbs Therapeutics | Y-mAbs Therapeutics, Inc | Y-mABs Therapeutics, Inc | Y-MABS THERAPEUTICS INC